Preparing for the next phase of cell and gene therapy
Cell and gene therapy (CGT) is entering a new phase of growth as therapies expand beyond early oncology applications into broader and more operationally complex indications affecting larger patient populations. For health systems, that shift creates both opportunity and risk. Some organizations are evaluating whether to enter CGT for the first time. Others already administer CGT and need a more scalable, repeatable model to expand across therapies, sites, and service lines.
CGT enablement consulting helps health systems assess readiness, clarify financial and operational considerations, and plan for launch or expansion with greater confidence. By combining readiness assessment, financial modeling, governance design, and practical execution support, Accelerate Pharmacy Solutions helps health systems reduce uncertainty, strengthen execution, and build a more repeatable foundation for long-term program growth.
How we help health systems prepare for sustainable CGT growth
Financial confidence
Operational readiness
Scalable growth
Backed by deep CGT expertise and built specifically for health systems
Practical and execution-focused
We help health systems move from assessment to action with support tailored to their priorities, readiness, and internal capacity.
Connected across key functions
We connect planning across pharmacy, patient access, finance, operations, and compliance to support more aligned decisions and more consistent execution.
Informed by Cencora upstream CGT experience¹
We bring broader CGT insight across consulting, patient support, market access, and complex therapy logistics to guide health system decisions.
¹ Upstream CGT experience includes engagements across biopharma manufacturers, academic research, Contract Research Organizations, Contract Development and Manufacturing Organizations, and study sponsors.
Connect with our team